{"id":55627,"date":"2023-04-10T12:03:15","date_gmt":"2023-04-10T10:03:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/next-generation-sequencing-services-market-research-report-2023-a-24-5-billion-market-by-2030-decline-in-sequencing-prices-driving-growth-researchandmarkets-com\/"},"modified":"2023-04-10T12:03:15","modified_gmt":"2023-04-10T10:03:15","slug":"next-generation-sequencing-services-market-research-report-2023-a-24-5-billion-market-by-2030-decline-in-sequencing-prices-driving-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/next-generation-sequencing-services-market-research-report-2023-a-24-5-billion-market-by-2030-decline-in-sequencing-prices-driving-growth-researchandmarkets-com\/","title":{"rendered":"Next-generation Sequencing Services Market Research Report 2023: A $24.5 Billion Market by 2030 – Decline In Sequencing Prices Driving Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Next-generation Sequencing Services Market Size, Share & Trends Analysis Report By Service Type (Human Genome Sequencing, Gene Regulation Services), By Workflow, By End-use, And Segment Forecasts, 2023 – 2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.<\/p>\n

<\/a><\/p>\n

\nThe global next-generation sequencing services market size is expected to reach USD 24.5 billion by 2030 It is expected to expand at a CAGR of 22.56% from 2023 to 2030.<\/p>\n

\nThe development of next-generation sequencing (NGS) technologies has revolutionized gene sequencing in terms of reproducibility and cost savings. This has resulted in the introduction of several advancements in NGS technology to promote its usage in clinical labs and hospitals. Most current innovations in this field revolve around simplifying the usage of seq-technology and making it more sophisticated. These factors have driven the uptake of NGS services across various end-users.<\/p>\n

\nNext-generation sequencing has progressed from research to clinical use in the last five years. Around 14 nations have launched large-scale genome sequencing programs, with nearly 60 million people expected to have their genome analyzed by 2025. Conventional disease testing service providers have broadened their portfolio with a rising trend of seq-based genetic tests.<\/p>\n

\nFor instance, ARUP Laboratories announced the release of new coronavirus tests in March 2022, and IDbyDNA, Inc. partnered with another firm to introduce new coronavirus tests, an NGS test for respiratory illnesses, to aid physicians in evaluating patients with pneumonia and some other respiratory problems.<\/p>\n

\nWith the rising trend of high throughput sequencing within the pharma and biotech industry, there is a need for more developments to improve the speed and convenience of high throughput seq-platforms and simplify workflows. As a result, companies are focusing on the development of solutions to simplify the amplification and purification of samples and starting input.<\/p>\n

\nIn March 2022, Illumina, Inc. announced the release of TruSigh Oncology (TSO) Comprehensive (EU), a comprehensive diagnostic that evaluates several tumor genes and indicators to identify a patient’s cancer’s individual molecular profile. The in vitro diagnostic (IVD) kit would assist in influencing genomic decisions for patients with cancer across Europe, with its global debut taking place first in Europe.<\/p>\n

\nNext-generation Sequencing Services Market Report Highlights<\/strong><\/p>\n